Literature DB >> 26801502

Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment.

Yasuhiro Iesato1, Akira Imai1, Takao Hirano1, Yuichi Toriyama1, Toshinori Murata2.   

Abstract

PURPOSE: To investigate the effect of leaking capillaries and microaneurysms (MAs) in the perifoveal capillary network (PCN) on the treatment of fovea-involving macular edema (ME) secondary to branch retinal vein occlusion (BRVO) by intravitreal ranibizumab (IVR) injections combined with focal, grid, and scatter laser photocoagulation.
METHODS: Retrospective comparative case series. The MA (+) group consisted of 12 patients with leaking MAs in the PCN and the MA (-) group contained 11 patients without. At 6 months following the initial IVR injection, best corrected visual acuity (BCVA) was evaluated as the primary outcome. Secondary outcomes included central macular thickness (CMT) and the number of IVR injections performed in a pro re nata (PRN) regimen when CMT was ≥300 µm and vision deteriorated by 0.1 logMAR or greater.
RESULTS: Mean BCVA improved by 0.30 ± 0.25 logMAR in the MA (-) group and 0.28 ± 0.20 logMAR in the MA (+) group (both P < 0.0001). Mean CMT was reduced by 237.6 ± 221.4 µm (P < 0.0001) in the MA (-) and 158.2 ± 152.1 µm (P < 0.01) in the MA (+) group. The degrees of improvement in BCVA (P = 0.74) and CMT (P = 0.33) did not vary significantly between the groups. The mean number of additional IVR injections was significantly less in the MA (-) group than in the MA (+) group (2.2 ± 1.0 vs 3.0 ± 0.8; P = 0.04).
CONCLUSIONS: Although leaking MAs and capillaries in the PCN did not adversely affect improvements in BCVA and CMT, these manifestations led to an increased number of IVR injections needed to sustain resolution of ME involving the fovea.

Entities:  

Keywords:  Branch retinal vein occlusion; Focal/grid laser; Macular edema; Perifoveal capillary network; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 26801502     DOI: 10.1007/s10384-016-0425-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  32 in total

1.  Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

Authors:  Simone Donati; Paolo Barosi; Marco Bianchi; Muna Al Oum; Claudio Azzolini
Journal:  Eur J Ophthalmol       Date:  2012 Jul-Aug       Impact factor: 2.597

2.  Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Sharon Solomon; Ingrid Zimmer-Galler; Akrit Sodhi; Elia Duh; Howard Ying; Adam Wenick; Syed Mahmood Shah; Diana V Do; Quan D Nguyen; Saleema Kherani; Raafay Sophie
Journal:  Ophthalmology       Date:  2015-05-09       Impact factor: 12.079

3.  Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema.

Authors:  Ravi D Patel; Leonard V Messner; Bruce Teitelbaum; Kimberly A Michel; Seenu M Hariprasad
Journal:  Am J Ophthalmol       Date:  2013-02-27       Impact factor: 5.258

4.  Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.

Authors:  Mei Hong Tan; Ian L McAllister; Mark E Gillies; Nitin Verma; Gayatri Banerjee; Lynne A Smithies; Wan-Ling Wong; Tien Y Wong
Journal:  Am J Ophthalmol       Date:  2013-10-07       Impact factor: 5.258

5.  Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion.

Authors:  Elvira Farese; Gilda Cennamo; Nunzio Velotti; Claudio Traversi; Michele Rinaldi; Giuseppe De Crecchio
Journal:  Eur J Ophthalmol       Date:  2014-02-26       Impact factor: 2.597

6.  Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

7.  Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.

Authors:  Raafay Sophie; Gulnar Hafiz; Adrienne W Scott; Ingrid Zimmer-Galler; Quan Dong Nguyen; Howard Ying; Diana V Do; Sharon Solomon; Akrit Sodhi; Peter Gehlbach; Elia Duh; David Baranano; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2013-10       Impact factor: 5.258

8.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Syed Mahmood Shah; Quan Dong Nguyen; Howard Ying; Diana V Do; Edward Quinlan; Ingrid Zimmer-Galler; Julia A Haller; Sharon D Solomon; Jennifer U Sung; Yasmin Hadi; Kashif A Janjua; Nida Jawed; David F Choy; Joseph R Arron
Journal:  Mol Ther       Date:  2008-02-05       Impact factor: 11.454

9.  Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion.

Authors:  D Finkelstein
Journal:  Arch Ophthalmol       Date:  1992-10

10.  Intravitreal bevacizumab alone or combined with macular laser photocoagulation for recurrent or persistent macular edema secondary to branch retinal vein occlusion.

Authors:  Takafumi Hirashima; Tomoyuki Chihara; Toshitaka Bun; Takao Utsumi; Miou Hirose; Hideyasu Oh
Journal:  J Ophthalmol       Date:  2014-07-07       Impact factor: 1.909

View more
  9 in total

1.  Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.

Authors:  Takao Hirano; Yuichi Toriyama; Yasuhiro Iesato; Akira Imai; Kazutaka Hirabayashi; Taiji Nagaoka; Yoshihiro Takamura; Masahiko Sugimoto; Toshinori Murata
Journal:  Jpn J Ophthalmol       Date:  2016-10-11       Impact factor: 2.447

2.  Extended field imaging using swept-source optical coherence tomography angiography in retinal vein occlusion.

Authors:  Shinji Kakihara; Takao Hirano; Yasuhiro Iesato; Akira Imai; Yuichi Toriyama; Toshinori Murata
Journal:  Jpn J Ophthalmol       Date:  2018-03-28       Impact factor: 2.447

Review 3.  Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2018-03-23       Impact factor: 2.447

4.  Reduced light sensitivity due to impaired retinal perfusion in branch retinal vein occlusion.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2017-11-01       Impact factor: 2.447

5.  Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment.

Authors:  Toshinori Murata; Mineo Kondo; Makoto Inoue; Shintaro Nakao; Rie Osaka; Chieko Shiragami; Kenji Sogawa; Akikazu Mochizuki; Rumiko Shiraga; Takeumi Kaneko; Chikatapu Chandrasekhar; Akitaka Tsujikawa; Motohiro Kamei
Journal:  Sci Rep       Date:  2022-05-10       Impact factor: 4.996

6.  Morphologic Classifications and Locations of Microaneurysms and Clinical Relevance in Branch Retinal Vein Occlusion.

Authors:  Yuya Esaki; Yoshio Hirano; Ryo Kurobe; Yusuke Yasuda; Taneto Tomiyasu; Norihiro Suzuki; Tsutomu Yasukawa; Munenori Yoshida; Yuichiro Ogura
Journal:  Clin Ophthalmol       Date:  2020-07-06

Review 7.  New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion.

Authors:  Jia Li; Yannis M Paulus; Yuanlu Shuai; Wangyi Fang; Qinghuai Liu; Songtao Yuan
Journal:  J Ophthalmol       Date:  2017-03-12       Impact factor: 1.909

8.  Diabetic vascular hyperpermeability: optical coherence tomography angiography and functional loss assessments of relationships among retinal vasculature changes.

Authors:  Mitsuru Arima; Shintaro Nakao; Yoshihiro Kaizu; Iori Wada; Muneo Yamaguchi; Kohta Fujiwara; Masato Akiyama; Alan W Stitt; Koh-Hei Sonoda
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

9.  The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients.

Authors:  Toshinori Murata; Mineo Kondo; Makoto Inoue; Shintaro Nakao; Rie Osaka; Chieko Shiragami; Kenji Sogawa; Akikazu Mochizuki; Rumiko Shiraga; Yohei Ohashi; Takeumi Kaneko; Chikatapu Chandrasekhar; Akitaka Tsujikawa; Motohiro Kamei
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.